Alyeska Investment Group
UBX

Alyeska Investment Group’s Unity Biotechnology UBX Stock Holding History

Alyeska Investment Group’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,286,000
Closed -$2.48M – 624
2023
Q4 		$2.48M Hold
1,286,000
– – 0.02% 358
2023
Q3 		$3.09M Hold
1,286,000
– – 0.02% 364
2023
Q2 		$3.28M Hold
1,286,000
– – 0.02% 369
2023
Q1 		$2.1M Buy
+1,286,000
New +$5.15M 0.02% 351
2022
Q4 		– Sell
-128,600
Closed -$5.08M – 517
2022
Q3 		$5.08M Buy
+128,600
New +$811K 0.06% 266

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alyeska Investment Group's UBX Position: Q2 2025 in Review

Alyeska Investment Group sold out of Unity Biotechnology (UBX) in Q2 2025, closing a stake of 292,091 shares — an estimated $304K sold.

Alyeska Investment Group first reported a position in UBX in Q2 2018 and held it in 11 quarters. The position peaked at $5.08M in Q3 2022. 35 funds tracked by Wall St. Rank hold UBX as of Q2 2025.

  • Alyeska Investment Group reported no remaining Unity Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 292,091 Unity Biotechnology shares in Q2 2025, an estimated $304K.
  • Alyeska Investment Group first reported a position in Unity Biotechnology in Q2 2018 and held it in 11 quarters.
  • Alyeska Investment Group's Unity Biotechnology position peaked at $5.08M in Q3 2022.
  • 35 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2025.

Based on Alyeska Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.